Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Cancer Res. 2014 Aug 12;74(19):5553–5560. doi: 10.1158/0008-5472.CAN-14-0209

Table 3.

Latency analysis of GBV-C infection and NHL

	GBV-C RNA Positivity^a							E2 Antibody Positivity^b

Latency		Controls		Cases	OR	95%	CI		Controls		Cases	OR	95%	CI
	N	%	N	%				N	%	N	%

0-0.99 year	2	0.58	3	1.73	3.00	(0.50	, 17.93)	20	5.78	8	4.62	0.79	(0.35	, 1.83)
1-3.99 years	3	0.64	3	1.28	2.00	(0.40	, 9.91)	31	6.62	16	6.84	1.04	(0.55	, 1.95)
4.00+ years^c	2	0.40	6	2.39	6.00	(1.21	, 29.73)	33	6.57	21	8.37	1.33	(0.73	, 2.42)

^a

Referent group is RNA-negative subjects.

^b

Referent group is E2 antibody-negative subjects.

^c

Mean=7.3 years (range 4.0 to 14.6 years)